149 related articles for article (PubMed ID: 20552300)
1. S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis.
Huang J; Cao Y; Wu L; Liao C; He Y; Gao F
Med Oncol; 2011 Dec; 28(4):1004-11. PubMed ID: 20552300
[TBL] [Abstract][Full Text] [Related]
2. S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials.
Li DH; Pan ZK; Ye F; An HX; Wu JX
Tumour Biol; 2014 Aug; 35(8):8201-8. PubMed ID: 24850178
[TBL] [Abstract][Full Text] [Related]
3. A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.
Wu FL; Lu DC; Ying YP; Huang JJ; Zhou AM; Jiang DK; Chen MW; Yang X; Zhou J; Huang HQ; Zeng HY
Medicine (Baltimore); 2015 Apr; 94(16):e652. PubMed ID: 25906091
[TBL] [Abstract][Full Text] [Related]
4. Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis.
Chen XD; He FQ; Chen M; Tang LC; Tang XL
Medicine (Baltimore); 2016 Jun; 95(24):e3916. PubMed ID: 27310997
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials.
Luo D; Wang L; Chen X; Xiong Y; Yi F; Ding J; Ding H; Wei Y; Zhang W
Chemotherapy; 2020; 65(1-2):11-20. PubMed ID: 32535588
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.
Ter Veer E; Mohammad NH; Lodder P; Ngai LL; Samaan M; van Oijen MG; van Laarhoven HW
Gastric Cancer; 2016 Jul; 19(3):696-712. PubMed ID: 26754295
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.
Cao C; Zhang X; Kuang M; Gu D; He M; Chen J; Tang C
Cancer Sci; 2014 Aug; 105(8):1008-14. PubMed ID: 24974863
[TBL] [Abstract][Full Text] [Related]
8. S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
He MM; Wu WJ; Wang F; Wang ZQ; Zhang DS; Luo HY; Qiu MZ; Wang FH; Ren C; Zeng ZL; Xu RH
PLoS One; 2013; 8(12):e82798. PubMed ID: 24349363
[TBL] [Abstract][Full Text] [Related]
9. S-1-based therapy versus S-1 monotherapy in advanced gastric cancer: a meta-analysis.
Wu JR; Tang WZ; Chen X; Xie YT; Chen SY; Peng QL; Xie L; Deng Y; Li TJ; He Y; Wang J; Li S; Qin X
Tumour Biol; 2014 Apr; 35(4):3283-93. PubMed ID: 24390661
[TBL] [Abstract][Full Text] [Related]
10. S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis.
Liu GF; Tang D; Li P; Wang S; Xu YX; Long AH; Zhou NL; Zhang LL; Chen J; Xiang XX
World J Gastroenterol; 2014 Jan; 20(1):310-8. PubMed ID: 24415887
[TBL] [Abstract][Full Text] [Related]
11. The clinical outcomes of S-1 plus cisplatin for patients with advanced gastric cancer: A meta-analysis and systematic review.
Yang L; Wang X; Wang B; Chao P; Li D; Chai C
Medicine (Baltimore); 2018 Dec; 97(49):e12789. PubMed ID: 30544367
[TBL] [Abstract][Full Text] [Related]
12. S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis.
Yang J; Zhou Y; Min K; Yao Q; Xu CN
World J Gastroenterol; 2014 Sep; 20(33):11886-93. PubMed ID: 25206296
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
Zhang X; Cao C; Zhang Q; Chen Y; Gu D; Shen Y; Gong Y; Chen J; Tang C
PLoS One; 2014; 9(1):e84230. PubMed ID: 24392116
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials.
Feng Z; Yan P; Hou X; Feng J; He X; Yang K
Ann Palliat Med; 2020 May; 9(3):883-894. PubMed ID: 32389017
[TBL] [Abstract][Full Text] [Related]
15. S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Bian NN; Wang YH; Min GT
Int J Surg; 2019 Feb; 62():34-43. PubMed ID: 30641155
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials.
Liu H; Chen X; Sun J; Gao P; Song Y; Zhang N; Lu X; Xu H; Wang Z
Medicine (Baltimore); 2014 Nov; 93(25):e164. PubMed ID: 25437030
[TBL] [Abstract][Full Text] [Related]
17. Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.
Zhu L; Liu J; Ma S
Pathol Oncol Res; 2016 Oct; 22(4):853-61. PubMed ID: 27236591
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
Ter Veer E; Ngai LL; Valkenhoef GV; Mohammad NH; Anderegg MCJ; van Oijen MGH; van Laarhoven HWM
Sci Rep; 2017 Aug; 7(1):7142. PubMed ID: 28769123
[TBL] [Abstract][Full Text] [Related]
19. A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.
Chen JS; Chao Y; Hsieh RK; Cheng AL; Chen PM; Chiou TJ; Chao TY; Yeh KH; Chen LT; Whang-Peng J
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1281-9. PubMed ID: 20714726
[TBL] [Abstract][Full Text] [Related]
20. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
